{"name":"Teva Branded Pharmaceutical Products R&D LLC","slug":"teva-branded-pharmaceutical-products-r-d-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TV-44749","genericName":"TV-44749","slug":"tv-44749","indication":"Osteoarthritis pain","status":"phase_3"}]}],"pipeline":[{"name":"TV-44749","genericName":"TV-44749","slug":"tv-44749","phase":"phase_3","mechanism":"TV-44749 is a selective inhibitor of transient receptor potential vanilloid 1 (TRPV1) that reduces pain signaling by blocking capsaicin-sensitive nociceptors.","indications":["Osteoarthritis pain","Neuropathic pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQTDF4LUxMVGxtSmhRSDZPQk1iUHBGY3NPRHZDSkJSbmZJcmZ5SVRtTnFOeGx6bUZvQ0Q1Y3R2Ull5QnlLazJ0bHJwbXhNd01pWi1ZTEFTQnNPSmZ2SnBLSC0yQkRYa0Y1UlZsS0hHZGt3RVNVRlJIWGIydGNubjJXRmgycHJ4dlRNSm5kR3RpaGVDS0hiN2tvZFlWaDlaNjZaaEsyRXc0VEc3Qmw5b2VCbl93UTlSWHJ5ZzRV?oc=5","date":"2026-03-02","type":"trial","source":"Psychiatrist.com","summary":"Outcomes and Practice Patterns of Long-Acting Injectable Versus Oral Antipsychotics Among Patients With Bipolar I Disorder in the United States: A Hospital Database Analysis - Psychiatrist.com","headline":"Outcomes and Practice Patterns of Long-Acting Injectable Versus Oral Antipsychotics Among Patients With Bipolar I Disord","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxORUpUVGtUanJJUGd3Y3QtU1hublk5dnFwZUV5OVI2MG5zdkg0WFJZWEdBM1dVQTVJN2NlUUlCbWI1SE5SQVlaOGhsNXAzeWRQeEhSbjFEai1GVXBCell1eVhpdHJxY0k0ZEVaVW5iUEpzWWtqakVaSm5sYUZWR0pSemMtdVp2dXpXUklqX1NuVEk4UU5Zb0RVV1U0SElqckpU0gFWQVVfeXFMTXdJeTNOckMxWDVZeDlJZ1Q0OEU2M1c4TTZlbHRSek1tR2VhZl84T2Y2MUx6WDhlbEw0akpGMFBIVjdRRURsOEZxQTc4WldEejZUWWhTSWc?oc=5","date":"2025-07-29","type":"pipeline","source":"Law360","summary":"Teva, Amneal End Case Over Listing Inhaler IP In Orange Book - Law360","headline":"Teva, Amneal End Case Over Listing Inhaler IP In Orange Book - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNWTdoZTUxanFxUDhaYzl2WFJ3Y3dFSlNMVmg0R3lwbVVpTU1ubkVDVUM1a3psM0F0azRPZGRSWXF1aHlCeVVsZjR4enc4VUk4UllESGZQT0hvc0lGOW9Ka0pRUWZrMHdSSmhUeksxUzBsak9uYmJpczlvSVhMeUdDX2RqUmhqMDRJVGJSQl8tNjdtZzUyWTRKQzVvX1c?oc=5","date":"2025-05-30","type":"regulatory","source":"Pharmacy Times","summary":"FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease - Pharmacy Times","headline":"FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWWJxcHlBSmYzUjJSLWNKNjhwWHFiTnhhcjgyTWxrTnBUenBla2xCNVBORGFYSnJoLUZMTHM1TXNSZTMzUFlYNnZhSE44ZFFXRDZqaVpiTjEtbXJTcllPcktqaDlGazNnNW9FbzY0dlh1OGJJd215M3NIZmlzT1dpWGZyLXZtNXQ1RlBXTmFyZmtyMUdES29JaEpGMVV1NkZnV2NVbnJtR2Rnb2s?oc=5","date":"2025-01-23","type":"patent","source":"Life Science Leader","summary":"Court Ruling Alters the Calculus for Orange Book Patent Listings - Life Science Leader","headline":"Court Ruling Alters the Calculus for Orange Book Patent Listings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNT3NQeTNoSWJZV2ZqMC12LVJiYnp6bnZDVTEzaERMbkJVeUFxcjdsZzV1cV8xMURQRFJjUWYwTWROaFU5RmQtY3BKNU14T3d6UGhEX1l5Y3ZOdzBhSWZNLU1nR1pndmhGa0NmZ0NmZW1Dd0J4c3pmS1hBZXZfZjBwWHVhQVFDbUNn?oc=5","date":"2024-12-24","type":"patent","source":"JD Supra","summary":"Federal Circuit Decides Case Involving Orange Book Listing of Device Patents - JD Supra","headline":"Federal Circuit Decides Case Involving Orange Book Listing of Device Patents","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOYlFKNUpJMDJpUGpFN2pySFg1el9jVGJXZVFiTzBXX0tVV2hHcTZkNS1nT0pIQXlSVEFmTi1WdkRMSFByUmJkdm9WN1RpaEhNcEtPTTI3bjFnbUtteFJmYWdmWXhpWDNZSGpDVFdDaURNd2RoMTJaM2REVkxMc0dhUjVXWVFidHNsWFlIS3R3amEzcmhVdmQxZUdLWjl3QTJpUWJvbDktVEp3WG02QUtHVzVnbTlQcVYtUmc?oc=5","date":"2024-12-20","type":"regulatory","source":"Reuters","summary":"Teva loses US appeal to keep inhaler patents on FDA protected drug list - Reuters","headline":"Teva loses US appeal to keep inhaler patents on FDA protected drug list","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPYlpyTUV5c2hud2pTRGIzMGNzTEJ2U3dTYWoxSFI5R3hQajVzdTRKcTUwc1hJdnY2WHdaNlpwOWs1MHpqQ19Pcl9PU2o0dXBRbGgwTXNmbTVveGpJUW5NOWRKQk1kaGpibWFjbElYdDBpTDgxUVl1WUFLdS1vRlhaU1NHdUNhcmxUQTB5eUxzSTY5bW9vMzA5bUVacVR1VjY1?oc=5","date":"2024-08-06","type":"pipeline","source":"White & Case LLP","summary":"Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024 - White & Case LLP","headline":"Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024 - White & Case LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOdFRTT3NmdkNOSGN0NWhCa0VBRlp1M0xOYWZFMjE0OE5yZjNmWU5CVGVQalJ1VnF3VlhiUl9aU0xqZHY3V3B4aWhxbzVQR0NxWDVmQl9PNGpVa2JzQ21IQmV6WGc2b1h4TWlzVW8ydEdMaEI3OUI2ekxRUlIzMHpuM0U1R0lGcUMtMnRGdEVBYlE1M21ScTBiVXpVUlZMY0NvXzJZOWFGT29aUWhOQnpvdmZrQ0xjRC1OclEzbU1lTEZtYVVXMExWUWxGc1p6bnVVWGUzd3l6b01jbVhaRlpLMGFabmRGa00?oc=5","date":"2024-07-31","type":"pipeline","source":"WilmerHale","summary":"The Interplay: Key Decisions at the Intersection of Antitrust and Life Sciences - July 2024 - WilmerHale","headline":"The Interplay: Key Decisions at the Intersection of Antitrust and Life Sciences - July 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPNTRHQTYxdUh4ajNKa3h1clpDU3NaUDktQnA1aVRVaGxtSkNPaHc3ZnhBRGJxNXV0X2xLRTB5NlNwaUlnc0JzSzZEbnRNXzVXdlBpQTBiclVYNVhwUlMwSDhacnlmTjhPTTVmS0NJZ1pLaDc2a0djOTlVUmg1cmhwczB2ZXpFamRmaDFDWFViZ1pzRDNScVYyS3JabHJaV3VrbUNVbEIxZw?oc=5","date":"2024-06-18","type":"pipeline","source":"Holland & Knight","summary":"Orange Book Concerns Pick Up as Yet Another Issue for Pharmaceutical Manufacturers - Holland & Knight","headline":"Orange Book Concerns Pick Up as Yet Another Issue for Pharmaceutical Manufacturers - Holland & Knight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPckJiZXhPLVRnQ2sySWRLLVltdHpoaWF1aVh5VWdWMEFyRjhvaEVQODV4TFQtZzg0cVFDRU9MS3Bhb0VHYm14MzBzcjVPQU1EN0J2MEVDMzRRZV9XdVR4ek1EQlV3N3ZoU3VVandIYlV6SUlmQzQxSnBxMk9Tb3ZBNmZpb2NLMElDbk4wWWFIMklxdWxTcEptY0FlaTRRZDRMdFdZVFhTVE50X09paHEyOVU1LXY2MHFYMml1Z0JGcC02cHI1NC1MZS10blRqTUZVVnNYR0ZwQzRxUQ?oc=5","date":"2024-05-08","type":"pipeline","source":"VitalLaw.com","summary":"ANTITRUST—M.D. Pa.: Antitrust claims over Teva’s asthma inhalers will proceed (May 8, 2024) - VitalLaw.com","headline":"ANTITRUST—M.D. Pa.: Antitrust claims over Teva’s asthma inhalers will proceed (May 8, 2024)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPY0d5WnR5MnVvM3dCcFJQRXlGUW1aMC1PLXc4RHBBVV83LVNtdE1DRDUxcmZYV0toSGQ3VGpDR2FOQUEtSThkSjFXVm1UR0lsOTZ2MVZjbTdteHhxZXdpTFpqMzh4LTlWc0pDVVZZbV9EbWhLUFFidUlTcEZkZkhDNjZQeXlZZ0ZUTEhxZDkxUUl3dXR0cDNvZUlscDgwLXZLU3ZqOEtn?oc=5","date":"2024-04-11","type":"patent","source":"jonesday.com","summary":"FTC Weighs In on Orange Book Listing of Drug-Device Patents - jonesday.com","headline":"FTC Weighs In on Orange Book Listing of Drug-Device Patents","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-04-03","type":"pipeline","source":"The National Law Review","summary":"FTC’s Campaign Against Improper Orange Book Listings Continues with Amicus Brief in Teva’s Challenge of Amneal Asthma Inhaler ANDA - The National Law Review","headline":"FTC’s Campaign Against Improper Orange Book Listings Continues with Amicus Brief in Teva’s Challenge of Amneal Asthma In","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}